Eupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at William Blair

William Blair assumed coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Monday morning, MarketBeat reports. The brokerage issued an outperform rating on the stock.

A number of other brokerages also recently weighed in on EPRX. Cantor Fitzgerald boosted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. HC Wainwright lowered their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Finally, Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Up 2.8%

EPRX stock opened at $7.08 on Monday. The company has a market cap of $254.60 million, a price-to-earnings ratio of -6.87 and a beta of 1.27. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $9.32. The business has a 50 day moving average price of $8.18 and a two-hundred day moving average price of $6.94.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). On average, equities research analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter worth approximately $122,000. Ikarian Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at $4,606,000. Squadron Capital Management LLC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at $3,775,000. SummitTX Capital L.P. acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $1,328,000. Finally, Quadrature Capital Ltd acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $326,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.